CADTH calls for patient input on a new submission from Novartis for Ilaris

CADTH

24 November 2015 - CADTH has received notice of a pending submission from Novartis for canakinumab (Ilaris) for use by patients with systemic juvenile idiopathic arthritis.

For more details, go to: https://www.cadth.ca/canakinumab-7

Michael Wonder

Posted by:

Michael Wonder